Open Access<p>Predicted Efficacy of Once-Daily Extended-Release Oxcarbazepine (Oxtellar XR®) Monotherapy in Adults and Children with Partial-Onset Seizures: Exposure-Response Modeling and Simulation</p>
Author(s) -
Shamia L. Faison,
Roberto Goméni,
Shan Mendes,
Welton O’Neal,
Stefan Schwabe,
Azmi Nasser
Publication year - 2020
Publication title -
clinical pharmacology
Language(s) - English
Resource type - Journals
ISSN - 1179-1438
DOI - 10.2147/cpaa.s256972
Subject(s) - oxcarbazepine , cmin , medicine , antiepileptic drug , extended release , microcrystalline cellulose , epilepsy , pharmacology , pharmacokinetics , chemistry , cmax , carbamazepine , cellulose , organic chemistry , psychiatry
We conducted exposure-response modeling and simulations to compare the predicted efficacy of extended-release oxcarbazepine (OXC-XR), an oral once-daily (qd) antiepileptic drug, with that of immediate-release (IR) OXC twice-daily (bid) when the agents are used as monotherapy or adjunctive therapy in patients with epilepsy characterized by partial-onset seizures (POS).